Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York, NY.

Absci management is scheduled to participate in a fireside chat on Wednesday, February 5th at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: investors.absci.com.

About Absci

Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.

Investor ContactAlex KhanVP, Finance & Investor [e-mail]

Media [e-mail]